TIDMGDR
RNS Number : 1411V
Genedrive PLC
30 November 2023
genedrive plc
("genedrive" or "the Company" or "the Group")
Audited Final Results
genedrive plc (AIM: GDR), the near patient molecular diagnostics
company, announces its audited Final Results for the year ended 30
June 2023.
Financial Highlights
-- Loss for the year of GBP5.2m (2022: loss of GBP4.7m)
-- R&D spend of GBP3.9m (2022: GBP3.9m)
-- Cash at bank of GBP2.6m (2022: GBP4.6m)
Operational Highlights
-- Genedrive(R) MT-RNR1 ID Test receives positive final
recommendation in NICE's Early Value Assessment programme
-- Genedrive(R) MT-RNR1 commenced rollout in Greater Manchester hospitals
-- Commercial distribution agreements for Antibiotic Induced
Hearing Loss (AIHL) test in place covering Spain, France, Austria,
Greece, Saudi Arabia, Kuwait, Turkey and the Netherlands
-- UKCA marking achieved for new Genedrive(R) CYP2C19 pharmacogenetic test
-- Benefiting from GBP1.2m multi-partner grant awarded for the
validation of Genedrive(R) CYP2C19 ID Kit in time critical NHS
settings. The Company is expected to receive cGBP0.2m directly
-- The draft NICE guidance recommends CYP2C19 genotyping for
clopidogrel treatment and Genedrive(R) CYP2C19 ID test modelled to
be a clinically and cost-effective option. Final NICE
recommendations pending
-- Investor Placing Agreement of up to GBP5m secured with
GBP2.3m drawn down during the year and a further GBP0.6m drawdown
post year end
-- Pre-submission process ongoing with the Food and Drug
Administration ("FDA") to determine regulatory process and
requirements to place AIHL into the American market
James Cheek, CEO of genedrive plc, said: "I'm excited to be part
of a Company that is innovating pharmacogenetic testing by bringing
the test closer to the patient thereby making a real difference in
patients' lives and helping clinicians make quick insightful
decisions that improve patient safety. We continue to develop and
create solutions that challenge what is possible and improve
patient outcomes."
For further details please contact:
genedrive plc +44 (0)161 989 0245
James Cheek: CEO / Russ Shaw: CFO
Peel Hunt LLP (Nominated Adviser
and Joint Broker) +44 (0)20 7418 8900
James Steel / Patrick Birkholm
Walbrook PR Ltd (Media & Investor +44 (0)20 7933 8780 or genedrive@walbrookpr.com
Relations)
Anna Dunphy +44 (0)7876 741 001
About genedrive plc ( http://www.genedriveplc.com )
genedrive plc is a pharmacogenetic testing company developing
and commercialising a low cost, rapid, versatile, simple to use and
robust point of need pharmacogenetic platform for the diagnosis of
genetic variations. This helps clinicians to quickly access key
genetic information that will help them make the right choices over
the right medicine or dosage to use for an effective treatment.
Based in the UK, the Company is at the forefront of work on Point
of Care pharmacogenetics. Pharmacogenetics looks at how your
genetics impacts a medicines ability to work for you. Therefore, by
using pharmacogenetics, medicines can be made safer and more
effective. The Company has launched its flagship product, the
Genedrive(R) MT-RNR1 ID Kit, which is a single-use disposable
cartridge which circumvents the requirement for cold chain
logistics by providing temperature stable reagent test kits for use
on their proprietary test platform. This test allows clinicians to
make a decision on antibiotic use within 26 minutes, ensuring vital
care is delivered with no negative impact on the patient
pathway.
The Company has a clear commercial strategy focused on
accelerating growth through maximising in-market sales, geographic
and portfolio expansion and strategic M&A, and operates out of
its facilities in Manchester.
Chairman's Statement
Innovation for better health outcomes
This year has been both challenging and rewarding, the road to
commercialisation of groundbreaking innovative products is long and
challenging, due to the collection of data required and the sheer
size of the NHS and funding complexities of Integrated Care Systems
(ICS).
I am very pleased to see our Antibiotic Induced Hearing Loss
(AIHL) test in routine use at multiple sites, although initially on
a small scale, the Company is well positioned for geographical
expansion and I am immensely proud that we have contributed to the
prevention of hearing loss in infants, which when considered with
the NICE EVA recommendation and the potential to generate
significant savings for the NHS, sees us well poised to gain
growing commercial traction in the coming year.
Our people have worked relentlessly on the successful
development of the Genedrive(R) CYP2C19 ID test, which is our most
complicated assay developed to date and was delivered in the
shortest time frame. It was welcoming to see the draft guidance
from NICE recommending that CYP2C19 genotyping should be used
before clopidogrel administration in the management of ischemic
stroke patients and our inclusion in their Diagnostics Assessment
Programme is a remarkable achievement. The final NICE
recommendation, which had previously been expected in December
2023, has recently been delayed with further details not yet
available.
The DEVOTE programme, led by the University of Manchester (UoM),
builds on the model of the previous successful UoM/genedrive
partnership with the PALOH programme, which supported the
development and evaluation of the NICE recommended Genedrive(R)
MT-RNR1 ID Kit. The DEVOTE grant funding will see us benefit from
access to the Acute Medicine Unit and reduce clinical validation
costs that otherwise would have been fully borne by the Group.
During the year we have consistently advanced our efforts
towards transforming the way in which certain personalised medicine
can be delivered aiming to enhance health outcomes and bring about
health economic benefits.
Governance and People
I was delighted to welcome James Cheek and Gino Miele to the
Board both with effect from 11 September 2023. James brings
extensive commercial and operational experience at a senior level
through a successful career with established diagnostic companies
and joined as Chief Executive Officer, replacing David Budd. I
would like to thank David for his dedication and leadership over
the past seven years and wish him every success for the future.
Gino joined the Board as Chief Scientific Officer and has
considerable experience in the development of molecular diagnostic
technologies and systems and has been the R&D Director at
genedrive since 2015 and its predecessor Epistem since 2011.
The Board continues its commitment to maintaining its own
efficiency and competence, with an unwavering dedication to
ensuring that our governance framework, internal controls, values,
and culture are all in harmony with our strategic goals and the
Company's objectives.
Our people are the lifeblood of the Company, and I want to
express my gratitude to each and every one of them for their
unwavering resilience, innovative spirit, and unyielding
determination in both the development and delivery of our
products.
Funding
The Board continuously assesses the Group's requirements and
funding options that would bridge the gap before revenue generation
allows us to be self-sufficient. The Investor Placing Agreement
entered into on 31 March 2023 provided a committed facility of up
to GBP5m and to date the Group has received GBP2.9m (GBP2m initial
payment and further payments of GBP0.3m in June, July and November
2023). Further drawdowns are conditional on meeting certain share
trading criteria, which are set out in note 6 and were also set out
in the Company's circular issued on 24 April 2023 and therefore
further drawdowns cannot be considered as guaranteed. The Board is
planning for an equity or debt raise in early 2024 to support the
growth and development plans of the business and allow the Group to
continue to operate as a going concern. The Group does expect to
receive an R&D tax credit of cGBP0.8m in Q1 of 2024 which, if
received, would extend the cash runway (absent any further funding
received) towards the end of Q1 2024 and provide a longer window
for our planned financing activities. The Group's current cash
runway is limited; unaudited cash as at 23 November 2023 was GBP1m
and further funding will be required in early 2024 in order to
continue as a going concern. The further payment of GBP0.3m
pursuant to the Investor Placing Agreement announced on 29 November
2023 is due to be received shortly.
We also remain active in our pursuit of non-dilutive funding,
such as the DEVOTE programme and we have pushed ahead with
commercial opportunities outside of the UK, appointing eight
international distributors and achieving six product registrations.
We are continuing to work closely with the NHS to secure specialist
commissioning funding for our MT-RNR1 product, as well as
finalising our 2024 sales strategy and distribution channel for our
new CYP2C19 product. With our commercialisation strategy including
the US, we have recently completed a pre-submission exercise with
the FDA which has, with no predicate device, clarified what would
be expected to fulfil for release in the US of our novel MT-RNR1
test. We are now looking at funding options to take us forward for
FDA approval for the MT-RNR1 product, with substantially all of the
exploratory groundwork completed we are ready to proceed to the
next step. Future funding would also be required to support the
ongoing development of the instrumentation allowing us to
capitalise on our pharmacogenetic positioning in emergency care and
add further tests to our existing menu.
Outlook
Our mission is to leverage our technology to facilitate the
improvement of health outcomes and it is encouraging that we are
now beginning to bear the fruits of our labour. The Group will need
to raise further funds in early 2024 to allow us to continue to
operate as a going concern and fulfil our mission.
The Company will remain focused on its strengths, with a strong
research and development capability at the core of our company, we
will continually strive to grow our innovative product offering by
leveraging our extensive knowledge in developing novel in-vitro
pharmacogenetic assays.
Our Genedrive(R) platform is at the forefront, offering
efficient and speedy genetic testing solutions and has the
capability to address molecular pharmacogenetics in critical care
settings. By harnessing our extensive expertise in developing
in-vitro molecular diagnostic assays for use in time-critical
healthcare settings, coupled with the advantages of our evolving
Genedrive(R) platform, our company is establishing itself as a
pioneer in the implementation of pharmacogenetics within emergency
care.
We continue to make progress for FDA approval of our MT-RNR1
product, the US represents a very important market opportunity. As
there is no predicate product in the US, there is no defined
pathway for us to follow. The FDA have been very supportive of our
efforts throughout the process to date to bring this test to the US
market.
Finally, I want to express my appreciation to you, our valued
shareholders, as well as our staff and collaboration partners for
your ongoing support.
Dr Ian Gilham
Chairman
Chief Executive's Review
Innovation in Point-of-Care pharmacogenetic diagnostics in
Emergency Medicine
Overview
This year has marked significant progress in our efforts to
revolutionise the delivery of pharmacogenetic testing and
personalised medicine. We continue to seek out and address unmet
clinical requirements, capitalising on our proficiency in
developing in-vitro pharmacogenetic diagnostic assays.
The UKCA marking of the Genedrive(R) CYP2C19 test is testimony
to this and the use of our point-of-care test will allow patients
to be put on an optimised treatment plan much quicker than is
currently possible. I would like to take this opportunity to whole
heartedly thank the efforts of the entire team here at genedrive
for turning this ambitious and challenging vision into a reality in
an incredibly short time which is a real testament to the quality,
ability and dedication that we have in the organisation.
It is a privilege for the Group to once again collaborate with
our esteemed colleagues at the University of Manchester (UoM) and
Manchester University NHS Foundation Trust (MFT) in developing
time-critical genetic test solutions. The DEVOTE program is an
amazing opportunity to engage with the NHS to demonstrate the
effectiveness of a new diagnostic approach. Real time access to the
Acute Medicine Unit has considerable value to the Group and the
grant funding to genedrive and its partners allows us to expediate
the ongoing product development and support the pathway to clinical
validation of our Genedrive(R) CYP2C19 ID Kit. This level of
clinical input and evaluation is increasingly required by
regulatory authorities prior to marketing product especially in the
EU.
Our AIHL test is the world's first pharmacogenetic test in an
urgent neonatal point-of-care setting. It helps avoid lifelong
deafness in infants that are genetically predisposed to the
unintended toxic effects in the inner ear from certain antibiotics.
The test delivers a diagnostic result in under 30 minutes and
allows for alternative treatment selections depending on the
genetic variant of the patient.
Last year the Company took the strategic decision of
transferring instrument manufacturing operations to the UK and some
assay manufacturing in-house, with a view to increase visibility
and control of its processes. This cost beneficial action has
resulted in elevated transparency and oversight, whilst enhancing
the speed and flexibility in transportation and delivery, reducing
the time-to-market and improving sustainability. Bringing our
supply chain closer together, improves the Group's agility and
resiliency, with both economic and environmental advantages. This
was highlighted no better than in our ability to bring the CYP2C19
assay to market so quickly.
Performance
Both genedrive and our UK distributor have made significant
in-roads across both the Academic Health Science Networks and
individual Trusts, we truly believe that the clinical argument has
been won. The next step on our journey is to secure interim funding
until the date that the specialist commissioning kicks in to
support the adoption UK wide. In the meantime, we are not sitting
still and continue to establish distributors outside of the UK. We
are also funding several Key Opinion Leader presentation and
discussions across Europe and beyond. Our commercial team has made
solid progress in thirteen countries internationally as we find
wider interest in our products and our company worldwide.
Outlook
Using genetic and genomic testing for diagnosis and treatment
optimisation has seen a considerable upsurge in recent years. This
surge is propelled by rapid advancements in scientific knowledge
and technological innovation. I take great pride in witnessing
genedrive as a front runner in this field.
Our developments have facilitated remarkable advancements in
personalised medicine, making it possible to customise treatment
strategies for patients.
We are pioneers in what we do, so there is no well-trodden path
between our technological advances and the commercial benefits. The
NICE recommendation for our AIHL test demonstrates the beneficial
impact of the test to both patients and wider society, whilst
simultaneous providing potential and substantial cost savings to
the NHS and we see that as instrumental to our UK roll out and
expansion into international market.
Our focus remains on pharmacogenetic testing as we continue to
invest in product development focusing on maximising the benefits
of our continually advancing Genedrive(R) platform, characterised
by its compactness, user-friendliness, rapid results, precision,
and cost-effectiveness, qualities that makes it well-suited for
extensive adoption. We believe our products are uniquely positioned
for time-critical pre-emptive pharmacogenetic testing in emergency
care and we will continue to explore opportunities outside of
MT-RNR1 and CYP2C19.
James Cheek
Chief Executive Officer
Financial Review
Revenue for the year was GBP0.06m (2022: GBP0.05m) and continues
to reflect the time required for our products to gain commercial
traction. The MT-RNR1 test is in routine use in Greater Manchester,
paving the way for other early adopters in the UK, whereas
international revenues are dependent on product registration and
language translation, which has been achieved post year end in six
countries. Research and development costs were GBP3.9m (2022:
GBP3.9m) as we prepared for the regulatory approval of our second
molecular point of care assay effectively expanding our range of
assays and developing a pipeline for future innovative products.
Administration costs have been tightly managed reducing by GBP0.4m
from the prior year to GBP1.4m (2022: GBP1.8m). The operating loss
for the year was GBP5.2m (2022: GBP5.6m).
Financing costs and income
Financing costs were GBP0.8m (2022: GBP0.02m) including a
non-cash fair value adjustment in respect of the derivative
financial instrument of GBP0.7m (2022: GBPnil) and financing income
was GBP0.03m (2022: GBPnil)
Taxation
The tax credit for the year was GBP0.8m (2022: GBP1.0m). The
Group investment in R&D falls within the UK Government's
R&D tax relief scheme for small and medium sized companies
where it meets the qualifying criteria and as the Group did not
make a profit in the year it is collected in cash following
submission of tax returns. The GBP0.8m is a receivable on the
balance sheet at the year end and is lower than in the previous
year due to reductions in the enhanced relief available from April
2023.
Cash resources
Net cash outflow from operating activities before taxation was
GBP4.8m (2022: GBP5.8m). The operating loss cashflows were GBP4.9m
(2022: GBP5.3m) with a working capital inflow of GBP0.1m (2022:
outflow GBP0.4m) mainly due to the reduction in inventory.
The tax credit received was GBP1.0m (2022: GBP1.2m) and relates
to cash received under the UK Government's R&D tax relief
scheme.
Capital expenditure in the period was GBP0.05m (2022: GBP0.06m)
and the proceeds from investment funding, net of transaction costs
were GBP2.0m (2022: GBP6.7m). The decrease in cash for the year was
GBP2.0m (2022: GBP2.0m increase) meaning a closing cash position of
GBP2.6m (2022: GBP4.6m).
Our unaudited cash balance as at the 23 November 2023 was
GBP1.0m, reflecting a monthly burn rate of GBP0.4m since the year
end. The further payment of GBP0.3m pursuant to the Investor
Placing Agreement announced on 29 November 2023 is due to be
received shortly.
Funding
Requiring additional funding to finance the development of the
CYP2C19 project and commercialisation of AIHL, the Company entered
into an Investor Placing Agreement of up to GBP5m on 31 March 2023,
of which GBP2.3m was drawn down in the year to 30 June 2023 and a
further GBP0.6m since then. Further details can be found in note
6.
The Company also continues to actively seek non-dilutive funding
and participation in the DEVOTE programme will see the Company
receive cGBP0.2m and avoid a further cGBP1.0m of costs that would
otherwise have been absorbed by the Company for the validation and
verification of our CYP2C19 product.
Balance sheet
Balance sheet net assets at 30 June 2023 were GBP2.0m (2022:
GBP5.6m). Fixed assets were GBP0.4m (2022: GBP0.2m) and include
right to use lease assets of GBP0.2m (2022: GBP0.02m).
Current assets of GBP4.1m (2022: GBP6.4m) included cash of
GBP2.6m (2022: GBP4.6m). Inventories of GBP0.5m (2022: GBP0.7m),
consisted mainly of raw materials used in manufacturing and
R&D. The remainder of current asset values were in receivables
of GBP0.2m (2022: GBP0.1m) and tax. The tax receivable was GBP0.8m
(2022: GBP1.0m) for the current year Corporation Tax Research and
Development tax claim.
Current liabilities were GBP2.4m (2022: GBP1.0m) and include a
derivative financial instrument GBP1.3m (2022: GBPnil) resulting
from the Investor Placing Agreement, as set out in note 6.
The shares to be issued reserve of GBP0.5m (2022: GBPnil)
relates to the warrants issued as part of the Investor Placing
Agreement.
Net assets closed at GBP2.0m (2022: GBP5.6m). The comprehensive
loss for the year was GBP5.2m (2022: GBP4.7m).
Going concern
As outlined in the Chairman's statement, the Group and Company
needs to bridge the funding gap before revenue generation allows us
to be self-sufficient. The Board is actively considering financing
options. This short-term funding requirement is partly as a result
of the uncertainty of further drawdowns from the Investor Placing
Agreement which are conditional on certain factors including the
Company's share price. The Company remains in close dialogue with
the investors, further drawdowns would extend the cash runway and
therefore the timeline for our planned financing activities. The
Group does also expect to receive an R&D tax credit of cGBP0.8m
in Q1 of 2024 which, if received, would extend the cash runway
(absent any further funding received) towards the end of Q1 2024
and provide a longer window for our planned financing activities.
As well as equity or debt financing we are also actively seeking
non-dilutive funding such as grants, funding partners for the FDA
approval and charitable organisations willing to support the
adoption of our quality-of-life enhancing innovations.
We are beginning to gain commercial traction, RNR1 is in routine
use at a small number of hospitals and with the appointment of
international distributors, language packs and registrations
complete, we are confident that significant revenues will follow.
NHS specialist commissioning would expediate this, but as we are
not in control of the process, there is uncertainty as to the
timing.
The NICE EVA (Early Value Assessment) recommendation supports
our belief that our RNR1 test quickly and accurately identifies
babies, who may be at risk of hearing loss if given aminoglycoside
antibiotics, allowing equally effective alternative antibiotics to
be used instead and that the long-term savings to the NHS
associated with hearing loss and fitting cochlear implants could be
substantial.
As described in the accounting policies, we continue to adopt a
going concern basis for the preparation of the accounts, but the
combination of the above factors represent a material uncertainty
that may cast significant doubt on the Group and Company's ability
to continue as a going concern.
Russ Shaw
Chief Financial Officer
Consolidated Statement of Comprehensive Income
for the year ended 30 June 2023
Year ended Year ended
30 June 30 June
2023 2022
Note GBP'000 GBP'000
--------------------------------------------------- ---- ---------- ----------
Continuing operations
--------------------------------------------------- ---- ---------- ----------
Revenue 2 55 49
--------------------------------------------------- ---- ---------- ----------
Research and development costs (3,924) (3,871)
--------------------------------------------------- ---- ---------- ----------
Administrative costs (1,355) (1,793)
--------------------------------------------------- ---- ---------- ----------
Operating loss (5,224) (5,615)
--------------------------------------------------- ---- ---------- ----------
Finance costs 3 (757) (16)
--------------------------------------------------- ---- ---------- ----------
Loss on ordinary activities before taxation (5,981) (5,631)
--------------------------------------------------- ---- ---------- ----------
Taxation 4 831 956
--------------------------------------------------- ---- ---------- ----------
Loss for the financial year (5,150) (4,675)
--------------------------------------------------- ---- ---------- ----------
Loss/total comprehensive expense for the financial
year (5,150) (4,675)
--------------------------------------------------- ---- ---------- ----------
Loss per share (pence)
--------------------------------------------------- ---- ---------- ----------
- Basic and diluted 5 (5.5p) (5.5p)
--------------------------------------------------- ---- ---------- ----------
Consolidated Balance Sheet
as at 30 June 2023
30 June 30 June
2023 2022
Note GBP'000 GBP'000
------------------------------------ ---- -------- --------
Assets
------------------------------------ ---- -------- --------
Non-current assets
------------------------------------ ---- -------- --------
Property, plant and equipment 392 206
------------------------------------ ---- -------- --------
392 206
------------------------------------ ---- -------- --------
Current assets
------------------------------------ ---- -------- --------
Inventories 525 748
------------------------------------ ---- -------- --------
Trade and other receivables 158 107
------------------------------------ ---- -------- --------
Contingent consideration receivable - 15
------------------------------------ ---- -------- --------
Current tax asset 831 956
------------------------------------ ---- -------- --------
Cash and cash equivalents 2,601 4,589
------------------------------------ ---- -------- --------
4,115 6,415
------------------------------------ ---- -------- --------
Total assets 4,507 6,621
------------------------------------ ---- -------- --------
Liabilities
------------------------------------ ---- -------- --------
Current liabilities
------------------------------------ ---- -------- --------
Trade and other payables (935) (994)
------------------------------------ ---- -------- --------
Lease liabilities (222) (16)
------------------------------------ ---- -------- --------
Derivative financial instruments 6 (1,290) -
------------------------------------ ---- -------- --------
(2,447) (1,010)
------------------------------------ ---- -------- --------
Non-current liabilities
------------------------------------ ---- -------- --------
Lease liabilities (19) -
------------------------------------ ---- -------- --------
Total liabilities (2,466) (1,010)
------------------------------------ ---- -------- --------
Net assets 2,041 5,611
------------------------------------ ---- -------- --------
Equity
------------------------------------ ---- -------- --------
Called-up equity share capital 7 1,485 1,388
------------------------------------ ---- -------- --------
Other reserves 8 52,777 51,294
------------------------------------ ---- -------- --------
Accumulated losses (52,221) (47,071)
------------------------------------ ---- -------- --------
Total equity 2,041 5,611
------------------------------------ ---- -------- --------
Consolidated Statement of Changes in Equity
for the year ended 30 June 2023
Share Other Accumulated Total
capital reserves losses equity
GBP'000 GBP'000 GBP'000 GBP'000
---------------------------------------- -------- --------- ----------- --------
Balance at 30 June 2021 950 45,000 (42,358) 3,592
---------------------------------------- -------- --------- ----------- --------
Transactions with owners in their
capacity as owners:
Share issue 426 6,186 - 6,612
Share issue - deferred consideration 8 (8) - -
Equity-settled share-based payments 4 116 (38) 82
---------------------------------------- -------- --------- ----------- --------
Transactions settled directly in equity 438 6,294 (38) 6,694
---------------------------------------- -------- --------- ----------- --------
Total comprehensive loss for the year - - (4,675) (4,675)
---------------------------------------- -------- --------- ----------- --------
Balance at 30 June 2022 1,388 51,294 (47,071) 5,611
---------------------------------------- -------- --------- ----------- --------
Transactions with owners in their
capacity as owners:
---------------------------------------- -------- --------- ----------- --------
Share issue - 2 - 2
---------------------------------------- -------- --------- ----------- --------
Investment funding arrangement, net
of transaction costs 97 1,385 - 1,482
---------------------------------------- -------- --------- ----------- --------
Equity-settled share-based payments - 96 - 96
---------------------------------------- -------- --------- ----------- --------
Transactions settled directly in equity 97 1,483 - 1,580
---------------------------------------- -------- --------- ----------- --------
Total comprehensive loss for the year - - (5,150) (5,150)
---------------------------------------- -------- --------- ----------- --------
Balance at 30 June 2023 1,485 52,777 (52,221) 2,041
---------------------------------------- -------- --------- ----------- --------
Consolidated Cash Flow Statement
for the year ended 30 June 2023
Year ended Year ended
30 June 30 June
2023 2022
Note GBP'000 GBP'000
----------------------------------------------------- ---- ---------- ----------
Cash flows from operating activities
----------------------------------------------------- ---- ---------- ----------
Operating loss for the year (5,224) (5,615)
----------------------------------------------------- ---- ---------- ----------
Depreciation, amortisation and impairment 61 63
----------------------------------------------------- ---- ---------- ----------
Depreciation, right-of-use assets 193 187
----------------------------------------------------- ---- ---------- ----------
Share-based payment 96 38
----------------------------------------------------- ---- ---------- ----------
Operating loss before changes in working capital (4,874) (5,327)
----------------------------------------------------- ---- ---------- ----------
Decrease / (increase) in inventories 223 (192)
----------------------------------------------------- ---- ---------- ----------
(Increase) / decrease in trade and other receivables (51) 51
----------------------------------------------------- ---- ---------- ----------
Decrease in trade and other payables (59) (292)
----------------------------------------------------- ---- ---------- ----------
Net cash outflow from operating activities
before taxation (4,761) (5,760)
----------------------------------------------------- ---- ---------- ----------
Tax received 956 1,166
----------------------------------------------------- ---- ---------- ----------
Net cash outflow from operating activities (3,805) (4,594)
----------------------------------------------------- ---- ---------- ----------
Cash flows from investing activities
----------------------------------------------------- ---- ---------- ----------
Finance income 29 -
----------------------------------------------------- ---- ---------- ----------
Finance costs - (16)
----------------------------------------------------- ---- ---------- ----------
Acquisition of plant and equipment (52) (62)
----------------------------------------------------- ---- ---------- ----------
Proceeds from disposal of discontinued operations 15 107
----------------------------------------------------- ---- ---------- ----------
Net cash (outflow) / inflow from investing
activities (8) 29
----------------------------------------------------- ---- ---------- ----------
Cash flows from financing activities
----------------------------------------------------- ---- ---------- ----------
Proceeds from the investment placing agreement 6 2,300 -
Transaction costs relating to investment placing
agreement (283) -
Proceeds from share issue - 7,200
Transaction costs relating to share issue - (506)
Repayment of lease liabilities (193) (119)
Net inflow from financing activities 1,824 6,575
----------------------------------------------------- ---- ---------- ----------
Net (decrease) / increase in cash equivalents (1,989) 2,010
----------------------------------------------------- ---- ---------- ----------
Effects of exchange rate changes on cash and
cash equivalents 1 5
----------------------------------------------------- ---- ---------- ----------
Cash and cash equivalents at beginning of year 4,589 2,574
----------------------------------------------------- ---- ---------- ----------
Cash and cash equivalents at end of year 2,601 4,589
----------------------------------------------------- ---- ---------- ----------
Analysis of net funds
----------------------------------------------------- ---- ---------- ----------
Cash at bank and in hand 2,601 4,589
----------------------------------------------------- ---- ---------- ----------
Net cash 2,601 4,589
----------------------------------------------------- ---- ---------- ----------
Notes to the Financial Information
for the year ended 30 June 2023
General information
genedrive plc ('the Company') is a company incorporated and
domiciled in the UK. The registered head office is The CTF
Building, Grafton Street, Manchester M13 9XX, United Kingdom.
genedrive plc and its subsidiaries (together, 'the Group') is a
molecular diagnostics business developing and commercialising a
low-cost, rapid, versatile, simple-to-use and robust point-of-need
or point-of-care diagnostics platform for the diagnosis of
infectious diseases and for use in patient stratification
(genotyping), pathogen detection and other indications.
genedrive plc is a public limited company, whose shares are
listed on the London Stock Exchange Alternative Investment
Market.
1. Significant accounting policies
The financial information for the year ended 30 June 2022 has
been extracted from the Group's audited statutory financial
statements which were approved by the Board of Directors on 18
November 2022 and which have been delivered to the Registrar of
Companies for England and Wales. The report of the auditor on these
financial statements was unqualified, did not contain a statement
under Section 498(2) or Section 498(3) of the Companies Act
2006.
The report of the auditor on the 30 June 2023 statutory
financial statements was unqualified, did not contain a statement
under Section 498(2) or Section 498(3) of the Companies Act 2006,
but did draw attention to the Group's ability to continue as a
going concern by way of a material uncertainty paragraph.
The information included in this announcement has been prepared
on a going concern basis under the historical cost convention as
modified by the revaluation of financial assets and financial
liabilities (including derivative instruments) at fair value
through profit or loss, and in accordance with UK-adopted
International Accounting Standards.
The information in this announcement has been extracted from the
audited statutory financial statements for the year ended 30 June
2023 and as such, does not constitute statutory financial
statements within the meaning of section 435 of the Companies Act
2006 as it does not contain all the information required to be
disclosed in the financial statements prepared in accordance with
UK-adopted International Accounting Standards.
This announcement was approved by the board of directors on 29
November 2023 and authorised for issue via RNS.
Going concern
The Group's business activities, market conditions, principal
risks and uncertainties along with the Group's financial position
are described in the full annual accounts. The Group funds its
day-to-day cash requirements from existing cash reserves and
drawdowns from the Investor Placing Agreement, which are subject to
certain conditions as described in note 6. These matters have been
considered by the Directors in forming their assessment of going
concern.
The Directors have concluded that it is necessary to draw
attention to the revenue and cost forecasts in the business plans
during the period to June 2025. The Group and Company does not
currently have sufficient cash resources to continue as a going
concern during the forecast period due to the time expected to be
needed to gain commercial traction in its revenues. Therefore, the
Company will need to raise further equity, or other funding, in
early 2024 in order to continue as a going concern. The forecasts
prepared by the Directors include a plan to raise additional funds
from equity investors or debt providers in early 2024 to allow the
Company to continue as a going concern.
The Company is confident that given the health benefits and
economics that RNR1 will be a commercial success. The NICE EVA
(Early Value Assessment) recommendation is testimony to it. Our
CYP2C19 product is now at validation and verification stage and has
a much larger potential market than RNR1 with a far less complex
route to market. The Company recognises the uncertainty regarding
the timing of the associated revenues, given we are first to market
for RNR1 and the funding complexities within the NHS. NICE
recommendations and Specialist Commissioning will bring significant
upside to our sales forecasts, but they are outside of our control
and are therefore uncertain. The Directors have reasonable
confidence in their ability to raise additional funds given the
progress described above and having made enquiries, have a
reasonable expectation that the Group has access to adequate
resources to continue in operational existence for the foreseeable
future.
While the Board has a successful track record in raising funds,
there remains uncertainty as to the amount of funding that could be
raised from shareholders or debt providers. The combination of the
above factors represents a material uncertainty that may cast
significant doubt on the Group and Company's ability to continue as
a going concern.
Accordingly, the Directors have concluded that it is appropriate
to continue to adopt the going concern basis of accounting in
preparing these financial statements. These financial statements do
not include the adjustments that would result if the Group and
Company were unable to continue as a going concern.
2. Operating segments
For internal reporting and decision-making, the Group is
organised into one segment, Diagnostics. Diagnostics is
commercialising the Genedrive(R) point-of need molecular testing
platform. In future periods, and as revenue grows, the Group may
review management account information by type of assay and thus
split out Diagnostics into segments - however, for now, the single
segment is appropriate.
The chief operating decision-maker primarily relies on turnover
and operating loss to assess the performance of the Group and make
decisions about resources to be allocated to each segment.
Geographical factors are reviewed by the chief operating
decision-maker, but as substantially all operating activities are
undertaken in the UK, geography is not a significant factor for the
Group. Accordingly, only sales have been analysed into geographical
statements.
The results of the operating division of the Group are detailed
below.
Diagnostics Corporate
segment costs Total
Business segments GBP'000 GBP'000 GBP'000
-------------------------------------------- ----------- --------- --------
Year ended 30 June 2023
-------------------------------------------- ----------- --------- --------
Revenue 55 - 55
-------------------------------------------- ----------- --------- --------
Operating loss (3,869) (1,355) (5,224)
-------------------------------------------- ----------- --------- --------
Net finance costs (757)
-------------------------------------------- ----------- --------- --------
Loss on ordinary activities before taxation (5,981)
-------------------------------------------- ----------- --------- --------
Taxation 831
-------------------------------------------- ----------- --------- --------
Loss for the financial year (5,150)
-------------------------------------------- ----------- --------- --------
Total comprehensive expense for the year (5,150)
-------------------------------------------- ----------- --------- --------
Diagnostics Corporate
segment costs Total
Business segments GBP'000 GBP'000 GBP'000
-------------------------------------------- ----------- --------- --------
Year ended 30 June 2022
-------------------------------------------- ----------- --------- --------
Revenue 49 - 49
-------------------------------------------- ----------- --------- --------
Operating loss (3,822) (1,793) (5,615)
-------------------------------------------- ----------- --------- --------
Net finance costs (16)
-------------------------------------------- ----------- --------- --------
Loss on ordinary activities before taxation (5,631)
-------------------------------------------- ----------- --------- --------
Taxation 956
-------------------------------------------- ----------- --------- --------
Loss for the financial year (4,675)
-------------------------------------------- ----------- --------- --------
Total comprehensive expense for the year (4,675)
-------------------------------------------- ----------- --------- --------
Diagnostics Corporate
segment costs Total
GBP'000 GBP'000 GBP'000
------------------------ ----------- --------- --------
Year ended 30 June 2023
------------------------ ----------- --------- --------
Segment assets 960 3,547 4,507
------------------------ ----------- --------- --------
Segment liabilities (877) (1,589) (2,466)
------------------------ ----------- --------- --------
Year ended 30 June 2022
------------------------ ----------- --------- --------
Segment assets 1,003 5,618 6,621
------------------------ ----------- --------- --------
Segment liabilities (905) (105) (1,010)
------------------------ ----------- --------- --------
Additions to non-current assets: Diagnostics segment GBP353k
(2022: GBP124k) and Corporate costs GBP88k (2022: GBP31k).
Geographical segments
The Group's operations are located in the United Kingdom. The
following table provides an analysis of the Group's revenue by
customer location:
Year ended Year ended
30 June 30 June
2023 2022
All on continuing operations GBP'000 GBP'000
----------------------------- ---------- ----------
United Kingdom 35 37
Europe 16 10
United States of America 4 2
----------------------------- ---------- ----------
Rest of the world - -
----------------------------- ---------- ----------
55 49
----------------------------- ---------- ----------
Revenues from three customers accounted for more than 10% of
total revenue in the current year (2022: two).
3. Finance income/(costs)- net
Year ended Year ended
30 June 30 June
2023 2022
GBP'000 GBP'000
----------------------------------------------------------- ---------- ----------
Interest income on bank deposits 30 -
Transaction costs relating to investment placing agreement
(note 6) (81) -
----------------------------------------------------------- ---------- ----------
Movement in fair value of derivative financial instrument
(note 6) (675) -
----------------------------------------------------------- ---------- ----------
Finance lease costs (31) (16)
----------------------------------------------------------- ---------- ----------
(757) (16)
----------------------------------------------------------- ---------- ----------
4. Taxation
(a) Recognised in the income statement
Year ended Year ended
30 June 30 June
2023 2022
Current tax: GBP'000 GBP'000
------------------------------------- ---------- ----------
Research and development tax credits (831) (956)
------------------------------------- ---------- ----------
Total tax credit for the year (831) (956)
------------------------------------- ---------- ----------
(b) Reconciliation of the total tax credit
The tax credit assessed on the loss for the year is lower (2022:
lower) than the weighted average applicable tax rate for the year
ended 30 June 2023 of 20.5% (2022: 19.0%). The differences are
explained below:
Year ended Year ended
30 June 30 June
2023 2022
GBP'000 GBP'000
--------------------------------------------------------- ---------- ----------
Loss before taxation on continuing operations (5,981) (5,631)
--------------------------------------------------------- ---------- ----------
Tax using UK corporation tax rate of 20.5% (2022: 19.0%) (1,226) (1,070)
--------------------------------------------------------- ---------- ----------
Adjustment in respect of R&D tax credit claimed (295) (412)
--------------------------------------------------------- ---------- ----------
Items (taxable) for tax purposes - permanent 140 (7)
--------------------------------------------------------- ---------- ----------
Items not deductible for tax purposes - temporary (2) (3)
--------------------------------------------------------- ---------- ----------
Deferred tax not recognised 686 703
--------------------------------------------------------- ---------- ----------
Rate differences (134) (167)
--------------------------------------------------------- ---------- ----------
Total tax credit for the year (831) (956)
--------------------------------------------------------- ---------- ----------
No deferred tax assets are recognised at 30 June 2023 (2022:
GBPnil). Having reviewed future profitability in the context of
trading losses carried, it is not probable that there will be
sufficient profits available to set against brought forward
losses.
The Group had trading losses, as computed for tax purposes, of
approximately GBP21,676k (2022: GBP19,032k) available to carry
forward to future periods; this excludes management expenses.
5. Earnings per share
2023 2022
GBP'000 GBP'000
--------------------------------- -------- --------
Loss for the year after taxation (5,150) (4,675)
--------------------------------- -------- --------
2023 2022
Group Number Number
---------------------------------------------------- ---------- ----------
Weighted average number of ordinary shares in issue 94,165,295 84,860,240
---------------------------------------------------- ---------- ----------
Potentially dilutive ordinary shares - -
---------------------------------------------------- ---------- ----------
Adjusted weighted average number of ordinary shares
in issue 94,165,295 84,860,240
---------------------------------------------------- ---------- ----------
Loss per share on continuing operations
---------------------------------------------------- ---------- ----------
- Basic (5.5)p (5.5)p
---------------------------------------------------- ---------- ----------
- Diluted (5.5)p (5.5)p
---------------------------------------------------- ---------- ----------
The basic earnings per share is calculated by dividing the
earnings attributable to ordinary shareholders for the year by the
weighted average number of ordinary shares in issue during the
year.
As the Company is loss-making, no potentially dilutive options
have been added into the EPS calculation. Had the Company made a
profit in the period:
2023 2022
Group Number Number
------------------------------------------------------------ --------- ---------
Potentially dilutive shares from share options and warrants 1,163,817 971,238
------------------------------------------------------------ --------- ---------
Potentially dilutive shares within the SIP 339,967 208,703
------------------------------------------------------------ --------- ---------
Potentially dilutive ordinary shares 1,503,784 1,179,941
------------------------------------------------------------ --------- ---------
6. Derivative Financial Instruments
On 31 March 2023, the Company entered into an Investor Placing
Agreement for up to GBP5m with RiverFort Global Opportunities PCC
Limited ("Noteholders"). The instrument was entered by way of an
initial drawdown in the amount of GBP2m and related issuance of
6,250,000 shares priced at nominal value of 1.5 pence to be used to
facilitate the settlement of amounts advanced under the investment
agreement. A further drawdown was made in June 2023 of GBP0.3m and
the remaining balance as at the balance sheet date of GBP2.7m under
the Facility is available for the Company to drawdown, at its
discretion, but subject to there being no trading Material Adverse
Change:
(a) the Share Price falling below 16 pence
(b) the 3 day average volumes traded being less than
GBP100,000
(c) the 10 day average trading volumes being less than
GBP100,000 and
(d) the amount outstanding under the Facility being no more than
GBP700,000;
Any outstanding liability after the disposal by the Noteholder
of the shares issued in exchange for each drawdown can be settled
at the discretion of the Noteholder by further subscription to the
Company's shares. The Company can also elect to settle the
outstanding liability with a 10% premium on the balance. As the
value of the outstanding amount is expected to move with the
Company's share price, the instrument met the definition of a
derivative and is initially recognised at fair value with changes
in fair value recognised in profit and loss.
Pursuant to the facility, the Noteholders were granted warrants
exercisable at 41.6p to subscribe for 2,500,000 ordinary shares and
were granted warrants exercisable at 24.607p to subscribe for
682,731 ordinary shares. All warrants remain outstanding at 30 June
2023 and can be exercised at any time from the date of issue for a
period of four years.
The warrants are initially valued using a model which utilised
observable market factors such as the share price at the date of
the grant, the term of the award, the share price volatility and
the risk-free interest rate (Level 2 inputs).
The Company made drawdowns of GBP2.3m during the financial year
which can be summarised as follows:
Derivative
financial Finance
liability costs Equity Warrants Total
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
-------------------- ---------- -------- -------- -------- --------
Proceeds 615 - 1,117 568 2,300
Transaction costs - (81) (191) (91) (363)
-------- -------- -------- --------
615 (8 1 ) 926 477 1,937
-------------------- ---------- -------- -------- -------- --------
Fair value movement 675
-------------------- ----------
At 30 June 2023 1,290
-------------------- ----------
Transaction costs include fees of GBP80,000 payable to the
Noteholders that were settled by issue of shares and included in
share premium (note 8).
7. Share capital
Allotted, issued and fully paid:
Number GBP'000
-------------------------------------------------- ---------- -------
Balance at 30 June 2021 63,320,048 950
-------------------------------------------------- ---------- -------
Share issue - equity-settled share-based payments 271,546 4
Share issue - deferred consideration 500,000 8
Share issue 28,450,852 426
-------------------------------------------------- ---------- -------
Balance at 30 June 2022 92,542,446 1,388
-------------------------------------------------- ---------- -------
Share issue - equity-settled share-based payments 7,500 -
Share issue 6,500,000 97
-------------------------------------------------- ---------- -------
Balance at 30 June 2023 99,049,946 1,485
-------------------------------------------------- ---------- -------
On 1 October 2021 the Company issued 28,450,852 shares as part
of a placing and open offer to shareholders for net proceeds of
GBP6.6m.
On 10 December 2021 the Company issued 500,000 shares in
genedrive plc to the former owner of Visible Genomics as part of a
Deed of Amendment agreed in December 2018 to the Visible Genomics
Sale and Purchase Agreement.
On 3 April 2023 the Company issued 6,500,000 shares with a
nominal value of GBP97,000 as part of the Investor Placing
Agreement detailed in note 6.
8. Other reserves
Employee
share
Share Shares incentive Share Reverse
premium to be plan options acquisition Total
account issued reserve reserve reserve equity
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
------------------------------------- -------- -------- ---------- -------- ------------ --------
Balance at 30 June 2021 46,055 115 (196) 1,522 (2,496) 45,000
------------------------------------- -------- -------- ---------- -------- ------------ --------
Share issue - deferred consideration 107 (115) - - - (8)
Share issue 6,264 - - - - 6,264
Equity-settled share-based payments - - - 38 - 38
------------------------------------- -------- -------- ---------- -------- ------------ --------
Transactions settled directly in
equity 6,371 (115) - 38 - 6,294
------------------------------------- -------- -------- ---------- -------- ------------ --------
Balance at 30 June 2022 52,426 - (196) 1,560 (2,496) 51,294
------------------------------------- -------- -------- ---------- -------- ------------ --------
Investment funding arrangement
(note 6) 910 477 - - - 1,387
------------------------------------- -------- -------- ---------- -------- ------------ --------
Equity-settled share-based payments - - - 96 - 96
------------------------------------- -------- -------- ---------- -------- ------------ --------
Transactions settled directly in
equity 910 477 - 96 - 1,483
------------------------------------- -------- -------- ---------- -------- ------------ --------
Balance at 30 June 2023 53,336 477 (196) 1,656 (2,496) 52,777
------------------------------------- -------- -------- ---------- -------- ------------ --------
Shares to be issued relates to the warrants issued; full details
are contained in note 6.
The employee share incentive plan reserve is the historic cost
of shares purchased to satisfy share rights under the Share
Investment Plan ("SIP") of GBP196k. The Company no longer buys
shares to satisfy the SIP.
The reverse acquisition reserve arises as a difference on
consolidation under merger accounting principles and is solely in
respect of the merger of the Company and Epistem Ltd, during the
year ended 30 June 2007.
9. Post balance sheet events
The Company made two GBP0.3m drawdowns under the Investor
Placing Agreement (note 6) and issued 724,997 and 1,614,669
warrants to the Noteholders in July 2023 and November 2023
respectively.
The Company signed the DEVOTE funding grant post year end.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
FR DXBDBIXDDGXC
(END) Dow Jones Newswires
November 30, 2023 02:00 ET (07:00 GMT)
Genedrive (LSE:GDR)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Genedrive (LSE:GDR)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024